A different d-sotalol was associated with increased survival. The SWORD trial established that studies demonstrating a neutral effect on with cardiac failure amiodarone, digoxin drug for the treatment of AF. In patients siderations in choosing an antiarrythmic lol in such patients is not without signifi-

The use of verapamil, quinidine and sotalol.3 The current study describes 10 epi-

AF is common in ageing patients with ischaemic and structural heart disease. Data from this study suggests 20% of pa-

If anti-arrythmic agents are required for maintenance of sinus rhythm, their safety profile, together with individual pa-

References

1. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardio-


4. Coplen SE, Antman EM, Beritin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardio-

5. Finkielstein D, Schweitzer P. Role of angio-


Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial

To the Editor,

I read with interest the recent publication on the use of sotalol, quinidine and verap-

AF is common in ageing patients with ischaemic and structural heart disease. Data from this study suggests 20% of pa-

If anti-arrythmic agents are required for maintenance of sinus rhythm, their safety profile, together with individual pa-

References

1. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardio-


4. Coplen SE, Antman EM, Beritin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardio-

5. Finkielstein D, Schweitzer P. Role of angio-


Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial

To the Editor,

I read with interest the recent publication on the use of sotalol, quinidine and verap-

AF is common in ageing patients with ischaemic and structural heart disease. Data from this study suggests 20% of pa-

If anti-arrythmic agents are required for maintenance of sinus rhythm, their safety profile, together with individual pa-

References

1. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardio-


4. Coplen SE, Antman EM, Beritin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardio-

5. Finkielstein D, Schweitzer P. Role of angio-


Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial

To the Editor,

I read with interest the recent publication on the use of sotalol, quinidine and verap-

AF is common in ageing patients with ischaemic and structural heart disease. Data from this study suggests 20% of pa-

If anti-arrythmic agents are required for maintenance of sinus rhythm, their safety profile, together with individual pa-

References

1. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardio-


4. Coplen SE, Antman EM, Beritin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardio-

5. Finkielstein D, Schweitzer P. Role of angio-


Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial – Reply

To the Editor,

We share the concerns of Dr. Shelton concerning the safety of antiarrhythmic drug therapy. The intention of this trial, planned some years ago, was indeed to as-

We agree that amiodarone and dofeti-
lide are now the only drugs for which stud-

References

1. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardio-
